Johnson & Johnson (JNJ) Common Equity (2009 - 2026)
Johnson & Johnson (JNJ) posted Common Equity of $85.0 billion for Q2 2026, up 4.66% sequentially from $81.2 billion in Q1 2026, and up 8.28% YoY from $78.5 billion in Q2 2025.
Johnson & Johnson (JNJ) Common Equity (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Common Equity for 18 years, with the latest figure at $85.0 billion in Q2 2026.
- Quarterly Common Equity rose 8.28% year-over-year to $85.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $85.0 billion (up 8.28% YoY) and the FY2025 annual result came in at $81.5 billion, up 14.06% from the prior year.
- Common Equity grew to $85.0 billion in Q2 2026 per JNJ's latest filing, from $81.2 billion in the prior quarter.
- Over five years, Common Equity peaked at $85.0 billion in Q2 2026 and troughed at $68.8 billion in Q4 2023.
- A 5-year average of $75.3 billion and a median of $74.7 billion in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity increased 16.98% in 2022, then dropped 10.46% in 2023.
- Over 5 years, Common Equity stood at $74.6 billion in 2022, then decreased by 7.81% to $68.8 billion in 2023, then grew by 3.95% to $71.5 billion in 2024, then grew by 14.06% to $81.5 billion in 2025, then rose by 4.2% to $85.0 billion in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $85.0 billion, $81.2 billion, and $81.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 80.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 84.97 Bn |
| Mar 29, 2026 | 81.19 Bn |
| Dec 28, 2025 | 81.54 Bn |
| Sep 28, 2025 | 79.28 Bn |
| Jun 29, 2025 | 78.47 Bn |
| Mar 30, 2025 | 78.11 Bn |
| Dec 29, 2024 | 71.49 Bn |
| Sep 29, 2024 | 70.16 Bn |
| Jun 30, 2024 | 71.54 Bn |
| Mar 31, 2024 | 70.02 Bn |
| Dec 31, 2023 | 68.77 Bn |
| Oct 1, 2023 | 71.23 Bn |
| Jul 2, 2023 | 76.41 Bn |
| Apr 2, 2023 | 70.87 Bn |
| Jan 1, 2023 | 76.80 Bn |
| Oct 2, 2022 | 74.60 Bn |
| Jul 3, 2022 | 76.36 Bn |
| Apr 3, 2022 | 74.71 Bn |
| Jan 2, 2022 | 74.02 Bn |
| Oct 3, 2021 | 70.27 Bn |